Key Details
Price
$0.11Annual ROE
425.33%Beta
1.31Events Calendar
Next earnings date:
Apr 01, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Apr 01, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 05, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at two upcoming investor conferences being held in New York City in April. In addition to the presentations, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the respective conferences.
Live webcast presentation on Wednesday, September 13th at 10:30 AM ET HOUSTON, TX / ACCESSWIRE / September 5, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY on Wednesday, September 13, 2023 at 10:30 AM ET.
Live moderated video webcast with members of CNS Pharmaceuticals management on Wednesday, May 3rd at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / April 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study on Wednesday, May 3, 2023 at 12:00 PM ET. As part of the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President, Clinical Operations of CNS Pharmaceuticals will discuss the progress of its ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
Investing in energy penny stocks? Here's some top tips The post Buying Energy Penny Stocks?
Live moderated video webcast with members of CNS Pharmacetucals management and Key Opinion Leader, Professor Michael Weller, MD, on Tuesday, April 4 th at 3:00 PM ET HOUSTON , March 29, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor GBM Spotlight Event on Tuesday, April 4, 2023 at 3:00 PM ET. As part of the event, John Climaco, Chief Executive Officer of CNS Pharmaceuticals will be joined by Key Opinion Leader Professor Michael Weller, MD, to discuss GBM, the unmet need and the work CNS Pharmaceuticals is doing to advance Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
FAQ
- What is the primary business of CNS Pharmaceuticals?
- What is the ticker symbol for CNS Pharmaceuticals?
- Does CNS Pharmaceuticals pay dividends?
- What sector is CNS Pharmaceuticals in?
- What industry is CNS Pharmaceuticals in?
- What country is CNS Pharmaceuticals based in?
- When did CNS Pharmaceuticals go public?
- Is CNS Pharmaceuticals in the S&P 500?
- Is CNS Pharmaceuticals in the NASDAQ 100?
- Is CNS Pharmaceuticals in the Dow Jones?
- When was CNS Pharmaceuticals's last earnings report?
- When does CNS Pharmaceuticals report earnings?
- Should I buy CNS Pharmaceuticals stock now?